12:00 AM
Jan 29, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 3-phosphoinositide dependent protein kinase-1 (PDPK1); protein kinase B (AKT; AKT1; PKB; PKBA); ribosomal protein S6 kinase 70kDa polypeptide 1 (R



In vitro studies suggest that small molecule allosteric inhibitors of PDPK1 could enhance the anti-tumor activity of PDPK1 inhibitors to help treat cancer. The C-terminal domain of PDPK1 contains the PDPK1-interacting fragment (PIF) that is used to recruit other kinases for phosphorylation by...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >